Articles

A short course of a low-dose corticosteroid eye drop can relieve inflammation with only a low increase in intraocular pressure.

The stated core foundation of the Women in Retina program is that “the best innovations happen when diverse people with different perspectives collaborate.” The program will help ESRS harness these perspectives and challenge the way things are done and allow for them to be done better.

Physicians may need to recognize issues and treat patients more holistically.

Although the standard of care remains the pharmaceutical option, surgeons would like to see other options for individualised treatment, including artificial intelligence and sustained-release technologies.

The contest will take place at EURETINA 2022 as part of World Retina Day on Saturday 3 September 2022 from 8.30am to 9.30am CEST in Hall X2/Channel 7.

One systematic review and meta-analysis finds bariatric surgery associated with fewer cases of diabetic retinopathy overall and of sight-threatening progression.

This year’s hybrid meeting will allow attendees to participate in person or virtually. Either way, this congress will offer a wealth of information to specialists covering all aspects of retinal diseases.

A team of investigators has found that myopic refractive error is linked with an increased risk of primary open-angle glaucoma, and they indicate that the connection has a genetic foundation.

Foundation Fighting Blindness is a driving force in advancing retinal gene therapies into clinical trials.

Moving past the eyes and into the brain: It is vital to think beyond the eye in the presence of visual impairment and blindness.

Zonular crises occur due to many different aetiologies, but ophthalmologists now have multiple tools available to solve complex problems and achieve excellent results in complex cases.

CAM encourages corneal healing in patients with ocular surface disease.

In a study, investigators found that no characteristics of inflammatory bowel disease are related to ocular manifestations of the disease.

The companies note that data from Study CPN-302 confirm the results in the first Phase 3 study, CPN-301, and they demonstrate the clear benefits of treating patients after cataract surgery with APP13007.

Dr Jayanth Sridhar shares a day in the life of an academic retina specialist.

Although off-label repackaged bevacizumab syringes appear to satisfy an urgent clinical and financial need for patients with a variety of retinal disorders, they are known to be associated with considerable public health concerns due to the risks posed to patients from compounding pharmacies’ lack of compliance with a variety of FDA requirements.

Genotyping and artificial intelligence are together starting to predict the progression of glaucoma in individual patients, sparing them from suboptimal treatments and side effects. Recent research efforts are exploring modifiable risk factors such as caffeine consumption.

Flavoprotein fluorescence could serve as a new biomarker, according to a Mount Sinai study. This measurement could potentially be used as a first-line indicator to monitor of glaucoma progression for the patient and the physician.

Recent reports of retinal atrophy have raised concerns on potential long-term safety.

Several issues may restimulate the virus in those patients with prior exposure.

84% of the patients who received a hybrid, acrylic IOL with a continuous transitional focus (CTF) optic to correct presbyopia were within 0.5 D of emmetropia.

The findings of this study may have revealed the crucial role of gene fragments in retinal development and vision.

A novel computational platform identifies top-performing viral vectors that could deliver gene therapies to the retina with maximum efficiency and precision.

While the surgeons reported that the BW filter provided higher contrast during nucleus and viscous removal and posterior capsular polishing, they subjectively reported no significant advantage of using a BW filter.

No effect when used with orthokeratology lenses for 2 years.

According to the Nanoscope Therapeutics, 6-month safety and efficacy data are expected in Q1 2023. MCO-010 gene therapy reprograms healthy retinal cells to make them photosensitive.

The companies will jointly develop 4D bio-fabricated corneal transplants for diseases that require endothelial keratoplasty and natural lenticule transplants.

The threshold limit value is increased for virus and bacterial eradication.

Eyes of mice lacking protective protein show signs similar to age-related macular degeneration.